All News
Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
Read Article
RA after 70: Too Old for bioDMARDs?
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
Read Article
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Links:
Dr. John Cush RheumNow ( View Tweet)
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 mg till wk 12
-TP2: cont SEC or switch to PBO till wk 104
⭐️SEC efficacious on JIA ACR30/70
⭐️74% w/ resolution of enthes
⭐️Median T2flare in PBO in TP2 = 453d
LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Excellent talk on SLE, APS abs pregancy
⭐️pregnancy counseling is important
⭐️aspirin 81mg in all pregnant SLE pts
⭐️do not discontinue HCQ
⭐️stable LN - can switch MMF to AZA
Abs#6888
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear.
Head to head JAK-i vs. non-TNFi interesting
Brilliant developing discussion
number needed to harm vs. number needed to treat
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Links:
Dr. John Cush RheumNow ( View Tweet)
Results: MTX vs. PBO
✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001)
✅HR for kidney AE on safety labs: 0.73 (0.59-0.91)
✔️HR for kidney AE clinical events: 0.87 (0.56-1.36)
✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
🤜MTX safe from kidney perspective if baseline CrCl 40+
🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
How does MTX affect kidney function/adverse events? Pre-specified analysis of DBRCT: MTX 15-20mg/wk (n=2391) vs. PBO (n=2395) both with folic acid over median f/u 23 months
✅We demonstrated kidney safety of MTX
⚡️⚡️Also a *suggestion* of LESS decline in eGFR for MTX than PBO https://t.co/SZXloLRmnj
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy?
⭐️Mean C3 ⬆️28% compared to 1st trimester
⭐️Mean C4 ⬆️ 11% compared to 1st trimester
@RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel
⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls
⭐️RTX lowest seropos of 39%, related to time of infusion
⭐️⬇️ with GC, ABA, MMF
⭐️ MTX not seen to significantly ⬇️
@RheumNow @rheum_covid
Eric Dein ejdein1 ( View Tweet)
#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database
88.4% live births, 10.5% preg loss, 0.8% still birth
2.4% congen malform (w/2.1% major)
Preg loss⬅️Crohn's, NSAIDS, MTX
Preterm labor⬅️GCs, maternal infx
⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge
k dao KDAO2011 ( View Tweet)
A single dose of LORECIVIVINT IA (Wnt pathway modulator) in Phase 3 study in knee OA: mild improvement of WOMAC pain -8.16[-15.60, -0.71] P=0.032 and function -9.47[-17.09, -1.84] P=0.015 at 6 and 12months with no particular safety signal. #POS0278 #EULAR2021 @RheumNow https://t.co/5qQE6MPjnU
Aurelie Najm AurelieRheumo ( View Tweet)
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal.
#LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2021 and EULAR IQ
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Links:
Dr. John Cush RheumNow ( View Tweet)
KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal.
#OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz
Aurelie Najm AurelieRheumo ( View Tweet)
